Marker Therapeutics FY 2025 net loss widens 13% to USD 12.16 million as grant income falls 46% to USD 3.55 million

Reuters03-19
Marker <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY 2025 net loss widens 13% to USD 12.16 million as grant income falls 46% to USD 3.55 million

Marker Therapeutics filed an annual report on Form 10-K reporting FY 2025 results, including grant income of USD 3.55 million, down 46%. Net loss for FY 2025 was USD 12.16 million, and net loss per share was USD 0.79. Research and development expense for FY 2025 was USD 11.8 million, down 12% primarily due to a net USD 3.2 million decrease in clinical trial expenses, mainly related to the AML study. Cash, cash equivalents, and restricted cash totaled USD 17.04 million at Dec. 31, 2025, and the company said it expects to fund operating expenses and capital expenditure requirements through Q4 2026, assuming no additional grant funds are received. Marker said the Phase 1 APOLLO study of MT-601 in relapsed lymphoma showed objective responses and a favorable safety profile with and without lymphodepletion, and it also reported first patient treatment in its off-the-shelf MT-401-OTS program with preliminary safety data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-031274), on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment